The next generation of "atypical" antipsychotics: The role of positron emission tomography;Die nächste generation "atypischer" antipsychotika: Der beitrag der positronenemissionstomographie

Fortschritte der Neurologie Psychiatrie

Volumn 71, Issue 8, 2003, Pages 415-420

  Gründer, Gerhard ^a,b   Wong, D F ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; PLACEBO; SEROTONIN 2 ANTAGONIST;

ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; DISSOCIATION; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; POSITRON EMISSION TOMOGRAPHY; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANTIPSYCHOTIC AGENTS; BRAIN; DOPAMINE AGONISTS; HUMANS; PSYCHOTIC DISORDERS; RECEPTORS, DOPAMINE D2; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0042861393     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-41194     Document Type: Article

References (42)

1. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49: 538-544
2. 2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988; 45: 71-76
3. 2A receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography (published erratum appears in Neuropsychopharmacology 1998 Aug; 19 (2): 161). Neuropsychopharmacology 1997; 17: 175-185
4. Meyer JH, Wilson AA, Ginovart N, Goulding V, Hussey D, Hood K, Houle S. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Am J Psychiatry 2001; 158: 1843-1849
5. Yokoi F, Gründer G, Biziere K, Stephane M, Dogan AS, Dannals RF, Ravert H, Suri A, Bramer S, Wong DF. Dopamine D(2) and D(3) Receptor Occupancy in Normal Humans Treated with the Antipsychotic Drug Aripiprazole (OPC 14597). A Study Using Positron Emission Tomography and [11C]Raclopride. Neuropsychopharmacology 2002; 27: 248-259
6. Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shiue CY, Cooper TB, Brodie JD. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 1989; 146: 905-908
7. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157: 514-520
8. 2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993; 33: 227-235
9. Lieberman JA, Carson WH, Saha A, Stringfellow JC, Archibald DG, Kujawa MJ, Ulwamoto T. Meta-analysis of the efficacy of aripiprazole in schizophrenia. Int J Neuropsychopharmacol 2002; 5 (Suppl 1): 186
10. Kane J, Ingenito G, Ali M. Efficacy of aripiprazole in psychotic disorders: Comparison with haloperidol and placebo. Schizophr Res 2000; 41: 39
11. Petrie JL, Saha AR, McEvoy JP. Aripiprazole, a new atypical antipsychotic: Phase 2 clinical trial result. Eur Neuropsychopharmacol 1997; 7 Suppl 2: 227
12. Saha AR, McQuade R, Carson WH, Ali MW, Dunbar GC, Ingenito G. Efficacy and safety of aripiprazole and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. World J Biol Psych 2001; 2 Suppl 1: 305
13. Saha AR, Ali M, Ingenito GG, Wilber R, Luo X, Bramer S. Safety and tolerability of aripiprazole at doses higher than 30 mg. Int J Neuropsychopharmacol 2002; 5 (Suppl 1): 185
14. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, Morita S. 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl}butyloxy]-3,4-dihydro-2(1H) -quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 1995; 274: 329-336
15. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, Mailman RB. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999; 20: 612-627
16. Inoue T, Domae M, Yamada K, Furukawa T. Effects of the novel antipsychotic agent 7-{4-[4-(2,3-dichlorophenyl)-1- piperazinyl]butyloxy}-3,4-dihydro-2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther 1996; 277: 137-144
17. Inoue A, Miki S, Seto M, Kikuchi T, Morita S, Ueda H, Misu Y, Nakata Y. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol 1997; 321: 105-111
18. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302: 381-389
19. Meller E, Bohmaker K, Namba Y, Friedhoff AJ, Goldstein M. Relationship between receptor occupancy and response at striatal dopamine autoreceptors. Mol Pharmacol 1987; 31: 592-598
20. Meller E, Enz A, Goldstein M. Absence of receptor reserve at striatal dopamine receptors regulating cholinergic neuronal activity. Eur J Pharmacol 1988; 155: 151-154
21. Benkert O, Gründer G, Wetzel H. Dopamine autoreceptor agonists in the treatment of schizophrenia and major depression. Pharmacopsychiatry 1992; 25: 254-260
22. Wetzel H, Hillert A, Gründer G, Benkert O. Roxindole, a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenic symptoms. Am J Psychiatry 1994; 151: 1499 - 1502
23. Gründer G, Vernaleken I, Benkert O. Welche Eigenschaften machen ein Neuroleptikum "atypisch". Nervenarzt 2001; 72: 833-843
24. Reynolds GP, Rossor MN, Iversen LL. Preliminary studies of human cortical 5-HT2 receptors and their involvement in schizophrenia and neuroleptic drug action. J Neural Transm 1983; 18 (Suppl): 273-277
25. 2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989; 25: 390-392
26. 2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology Berl 1993; 110: 365-367
27. 2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol 1995; 15: 19-23
28. 2A receptor occupancy in schizophrenic patients. Am J Psychiatry 1999; 156: 869-875
29. 2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998; 155: 921-928
30. Nyberg S, Farde L. Non-equipotent doses partly explain differences among antipsychotics - implications of PET studies [comment]. Psychopharmacology Berl 2000; 148: 22-23
31. Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 2001; 50: 873-883
32. Leucht S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002; 159: 180-190
33. Gründer G, Benkert O. Prolactin secretion is not a core dimension of atypicality. Psychopharmacology (letter) 2002; 162: 93
34. Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 1997; 280: 73-82
35. Scatton B, Claustre Y, Cudennec A, Oblin A, Perrault G, Sanger DJ, Schoemaker H. Amisulpride: from animal pharmacology to therapeutic action. Int Clin Psychopharmacol 1997; 12 Suppl 2: 29-36
36. Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, Oblin A, Gonon F, Carter C, Benavides J, Scatton B. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997; 280: 83-97
37. Seeman P. Atypical antipsychotics: mechanisms of action. Can J Psychiatry 2002; 47: 27-38
38. Vernaleken I, Siessmeier T, Buchholz H-G, Härtter S, Hiemke C, Stoeter P, Rösch F, Bartenstein P, Gründer G. High striatal occupancy of D2-like dopamine receptors by amisulpride in brain of schizophrenic patients: mechanism of action. submitted 2003
39. Wetzel H, Gründer G, Hillert A, Philipp M, Gattaz WF, Sauer H, Adler GJS, Rein W, Benkert O. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology - a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group. Psychopharmacology Berl 1998; 137: 223-232
40. Seeman P, Tallerico T. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 1999; 156: 876-884
41. 2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology Berl 1998; 135: 119-126
42. 2 receptor occupancy. Arch Gen Psychiatry 2000; 57: 553-559